STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 95075

TO: David Lukton **Location: cm-19b05/9b01** **Art Unit: 1653** **June 2, 2003** **Case Serial Number: 581511**	**From: P. Sheppard** **Location: CM1-1E03** **Phone: (703) 308-4499** **sheppard@uspto.gov**

Search Notes

Access DB# 95075

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: David Lukton Examiner #: 71263 Date: 05-27-03
Art Unit: 1653 Phone Number 30 8-3213 Serial Number: 09-581511
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL
MailBox: 9B01; Exr Rm: 9B05
If more than one search is submitted, please prioritize searches in order of need.

Title of Invention: HEMIASTERLIN ANALOGS

Applicants: Andersen, Raymond; Piers, Edward; NIEMAN, JAMES; COLEMAN, JOHN; ROBERGE, MICHEL

Earliest Priority Date: 12/19/97

* * * * * *

Applicants are claiming the compounds below

R^1, R^2, R^4 = anything;

R^5, R^6, R^7 = alkyl or hydrogen or phenyl;

R^3 is anything other than indole;

X = OH, NH_2, or OR^8

or else X is -NH-CH(R^9)-COOH

R^8 = alkyl

R^9 = anything



STAFF USE ONLY

Searcher: P. Sheppard (Point of Contact)
Telephone number: (703) 308-4499
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 6/2/03
Searcher Prep & Review Time: _____
Clerical Prep Time: _____
Online Time: _____

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN _____
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

PTO-1590 (8-01)

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 17:03:31 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Jun 2003  VOL 138 ISS 23
FILE LAST UPDATED: 1 Jun 2003  (20030601/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que 169
L52             STR
```




```
VAR G1=OH/NH2/16/18
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE
L55             STR
```





VAR G1=OH/NH2/16/18
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU
VAR G3=32/33/38/39/40/36/37
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE

L61		SCR 1840
L65	28	SEA FILE=REGISTRY SSS FUL L52 NOT L61
L66	17	SEA FILE=REGISTRY SSS FUL L52 AND L61
L67	45	SEA FILE=REGISTRY ABB=ON PLU=ON L65 OR L66
L68	43	SEA FILE=REGISTRY SUB=L67 SSS FUL L52 NOT L55
L69	25	SEA FILE=HCAPLUS ABB=ON PLU=ON L68

=>
=>

=> d ibib abs hitrn l69 1-25

L69 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:22860 HCAPLUS
DOCUMENT NUMBER: 138:90077
TITLE: Preparation of peptoid compounds for treatment of bacterial infections
INVENTOR(S): Bremner, John; Pyne, Stephen; Keller, Paul; Coghlan, Dan; Garas, Adel; Witchard, Helen; Boyle, Tim; Coates, Jonathan

PATENT ASSIGNEE(S): University of Wollongong, Australia
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002545	A1	20030109	WO 2002-AU850	20020628

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2001-6044 A 20010629
OTHER SOURCE(S): MARPAT 138:90077

AB The invention relates to new peptoid compds. A-Zr(CHR1)sCR2R3COBnNHCR4[CH2Wm(CH2)p-Y]CONHCR5R6(CH2)qCHR7CHR8aR8b [A is a (hetero)arom. ring system (or partially or fully reduced derivs.), which may be substituted by (cyclo)alkyl groups, a mono- or disaccharide moiety, or groups Xt-R9, where X = (CR10R11)x, NR12(CR10R11)x, (CR10R11)xNR12, O(CR10R11)x, (CR10R11)xO, etc.; n, m, r, t = 0 or 1; x, q = 0-4; R9 is H or forms a covalent bond with R8b; R10, R11 = H, OH, alkyl, aryl, alkoxy, an amino group; R12 = H, alkyl; Z = CR10R11, NR12, CO2, CONR12, or O; s = 0-3; R1, R2 = H, OH, alkyl, alkoxy, an amino or acylamino group; R3-R5 = H, alkyl, or side chains of .alpha.-amino acids; R6 = carboxy or phosphoryl or esters, carbamoyl, sulfonyl groups, etc.; R7, R8a = H or form a bond; B is an .alpha.- or .beta.-amino acid residue or an .alpha.,.alpha.-disubstituted amino acid residue; W is O or CR10R11; Y is an optionally substituted amino group or a moiety contg. an optionally substituted amino group; p = 0-6 (at least 1 when W is O)] for use in the treatment of bacterial infections such as those caused by vancomycin-resistant microorganisms. Thus, benzyl (R/S)-N-[3-(3'-allyl-2,2'-dimethoxy-1,1'-binaphth-3-yl)-2-acetamidopropionyl]-.epsilon.-(tert-butoxycarbonyl)-D-lysyl-L-allylglycine benzyl ester was prepd. via peptide coupling reaction and showed MIC = 4 .mu.g/mL for against S. aureus.

IT **484023-93-0P 484023-96-3P 484023-99-6P**
484024-16-0P 484024-17-1P 484024-20-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of peptoid compds. for treatment of bacterial infections)

IT **484024-21-7P 484024-62-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptoid compds. for treatment of bacterial infections)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:906473 HCAPLUS
DOCUMENT NUMBER: 138:16587
TITLE: Conjugates activated by cell surface proteases and therapeutic uses thereof
INVENTOR(S): Madison, Edwin L.; Semple, Joseph Edward; Vlasuk,

George P.; Kemp, Scott Jeffrey; Komandla, Mallareddy; Siev, Daniel Vanna
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: PCT Int. Appl., 581 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002095007	A2	20021128	WO 2002-US16819	20020523

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-293267P P 20010523
OTHER SOURCE(S): MARPAT 138:16587

AB Conjugates, compns. and method for treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases, are provided. The conjugates for use in the compns. and methods are peptidic conjugates that contain therapeutic, including cytotoxic, agents.

IT **476681-17-1D**, drug conjugates **476681-18-2D**, drug conjugates **476681-78-4D**, drug conjugates
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug conjugates activated by cell surface proteases for drug delivery)

L69 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:853427 HCAPLUS
DOCUMENT NUMBER: 138:304509
TITLE: The synthesis of a novel binaphthyl-based cyclic peptoid with anti-bacterial activity
AUTHOR(S): Bremner, John B.; Coates, Jonathan A.; Coghlan, Daniel R.; David, Dorothy M.; Keller, Paul A.; Pyne, Stephen G.
CORPORATE SOURCE: Department of Chemistry, University of Wollongong, Wollongong, 2522, Australia
SOURCE: New Journal of Chemistry (2002), 26(11), 1549-1551
CODEN: NJCHE5; ISSN: 1144-0546
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The novel cyclic peptoid I, based upon a 1,1'-binaphthyl scaffold and a bridging tripeptide moiety, was synthesized utilizing a ring-closing metathesis reaction. The individual major and minor diastereomers of compd. I were shown to have promising anti-bacterial activity against Staphylococcus aureus with inhibition of microbial growth at 17 .mu.L-1m (MIC) and 31 .mu.g ml-1, resp.

IT **509091-70-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of binaphthyl-based cyclic peptoid from dihydroxybinaphthyl using peptide coupling and ring-closing metathesis as key step)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:116981 HCAPLUS
DOCUMENT NUMBER: 137:149812
TITLE: A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease
AUTHOR(S): Narjes, Frank; Koehler, Konrad F.; Koch, Uwe; Gerlach, Benjamin; Colarusso, Stefania; Steinkuhler, Christian; Brunetti, Mirko; Altamura, Sergio; De Francesco, Raffaele; Matassa, Victor G.
CORPORATE SOURCE: Department of Chemistry, MRL Rome, IRBM, Rome, Pomezia, 00040, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 701-704
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The difluoromethyl group was designed by computational chem. methods as a mimetic of the canonical P1 cysteine thiol for inhibitors of the hepatitis C virus NS3 protease. This modification led to the development of competitive, non-covalent inhibitor AcAspGlu-NHCH(CHPH2)CO-Glu-NHCH(CH2C6H11)CONHCH(CH2CHF2)R (I, R = CHO) Ki 30 nM and reversible covalent inhibitors (I, R = CO2H) Ki 0.5 nM; and (I, R = COCO2H) Ki* 10 pM.

IT **444990-64-1**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:368424 HCAPLUS
DOCUMENT NUMBER: 133:12727

TITLE: Peptidic pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
INVENTOR(S): Pessi, Antonello; Ingallinella, Paola; Bianchi, Elisabetta
PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare p Angeletti Spa, Italy
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031129	A1	20000602	WO 1999-EP9207	19991124
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144446	A1	20011017	EP 1999-972641	19991124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: GB 1998-25946 A 19981126
WO 1999-EP9207 W 19991124
OTHER SOURCE(S): MARPAT 133:12727

AB Peptidic inhibitors of hepatitis C virus NS3 protease are disclosed which are based on the P and P' regions of the natural substrate. The P' part of the inhibitor is optimized to achieve max. binding energy through interaction with the S' region of the enzyme. By selecting amino acids such that the inhibitor is substantially not cleavable by the NS3 protease, inhibitors having potency in the low nanomolar to sub-nanomolar range can be achieved.

IT **272435-37-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(peptidic pharmaceutical compds. for inhibition of hepatitis C virus NS3 protease)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:671033 HCAPLUS
DOCUMENT NUMBER: 131:286829
TITLE: Preparation of peptides, peptide analogs and amino acid analogs as protease inhibitors
INVENTOR(S): Munoz, Benito; McDonald, Ian A.; Albrecht, Elisabeth
PATENT ASSIGNEE(S): Sibia Neurosciences, Inc., USA
SOURCE: U.S., 45 pp., Cont.-in-part of U. S. 5,804,560.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5969100	A	19991019	US 1995-403420	19950313

US 5804560	A	19980908	US 1995-369422	19950106	
US 5714471	A	19980203	US 1995-443901	19950517	
US 5962419	A	19991005	US 1995-442514	19950517	
US 6015879	A	20000118	US 1995-442662	19950517	
US 6051684	A	20000418	US 1995-442786	19950517	
US 6153171	A	20001128	US 1995-443048	19950517	
US 5863902	A	19990126	US 1995-444912	19950518	
US 5872101	A	19990216	US 1995-444361	19950518	
US 6017887	A	20000125	US 1995-443931	19950518	
CA 2209234	AA	19960711	CA 1996-2209234	19960105	
WO 9620725	A2	19960711	WO 1996-US360	19960105	
WO 9620725	A3	19961017			

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN

AU 9646973	A1	19960724	AU 1996-46973	19960105	
ES 2184850	T3	20030416	ES 1996-902650	19960105	

PRIORITY APPLN. INFO.: US 1995-369422 A2 19950106
US 1995-403420 A1 19950313
WO 1996-US360 W 19960105

OTHER SOURCE(S): MARPAT 131:286829

AB The title compds. represented by formulas R7-(Q)n-NR6CHR5CONR4CHR3CONR2CR1R8X (I), RBRACH-(Q)n-NR4CHR3CONR2CR1R8X (II), and RBRACH-(Q)n-NR2CR1R8X (III) [R1 is preferably 2-Me propene, 2-butene, norleucine; R2, R4, and R8 are each independently Me or ethyl; R3 is preferably iso-Bu or phenyl; R5 is preferably isobutyl; R6 is H or methyl; R7-(Q)n is preferably benzyloxycarbonyl or acetyl; Q is preferably CO; RB is preferably iso-butyl; RA = (T)m-(D)m-R1, in which T is preferably oxygen or carbon, and D is preferably a mono-unsatd. C3-4 alkenyl; X is an alc., particularly a secondary alc.] or their pharmaceutically acceptable salts, useful as protease inhibitors (no data), are prepd. A method for inhibiting a protease comprises contacting cells with a protease-inhibiting amt. of the compd. I, II, or III. A method for (1) treating a neurodegenerative disease (e.g. Alzheimer's disease, cognition deficits, Downs Syndrome, cerebral hemorrhage with amyloidosis, dementia pugilistica, and head trauma) characterized by the cerebral deposition of amyloid and (2) treating a patient suffering from a disease characterized by a degrdn. of the neuronal cytoskeleton resulting from a thrombolytic or hemorrhagic stroke comprises administering to the patient a therapeutically effective amt. of the compd. I, II, or III. Thus, Z-Leu-Leu-OH was condensed with Et 2-amino-4-methyl-4-pentenoate hydrochloride (prepn. given) using HOBT, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and Et3N in CH2Cl2 to give 47.3% Z-Leu-Leu-NHCH(CO2Et)CH2CMe:CH2 as a mixt. of diastereomers, which was reduced by LiBH4 in EtOAc at 0.degree. for 30 min to give 85.6% Z-Leu-Leu-NHCH(CH2OH)CH2CMe:CH2 as a mixt. of diastereomers.

IT **246242-59-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of peptidyl, peptidyl analog and amino acid analog alcs. as protease inhibitors for disease therapy)

REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:495313 HCAPLUS

DOCUMENT NUMBER: 131:127188

TITLE: Peptide inhibitors of the serine protease activity

associated with the NS3 protein of hepatitis C virus
INVENTOR(S): Pessi, Antonello; Steinkuhler, Christian; De Francesco, Raffaele
PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare, Italy
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938888	A2	19990805	WO 1999-IT22	19990202
WO 9938888	A3	19991007		
W: AU, CA, CN, IL, JP, KR, MX, NO, NZ, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IT 1299134	B1	20000229	IT 1998-RM61	19980202
CA 2319306	AA	19990805	CA 1999-2319306	19990202
AU 9925450	A1	19990816	AU 1999-25450	19990202
EP 1053249	A2	20001122	EP 1999-905173	19990202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509075	T2	20020326	JP 2000-529354	19990202

PRIORITY APPLN. INFO.: IT 1998-RM61 A 19980202
WO 1999-IT22 W 19990202

AB Subject of the invention are peptides capable of inhibiting the serine protease activity assocd. with the NS3 protein of hepatitis C viruses (HCV), their uses and a process for their prodn. In particular, proteolysis-derived peptides bearing in their C-terminal portion of their sequence the amino acids naturally occurring in the P4, P3, P2 and P1 positions (according to the definition of I. Schechter and A. Berger (1967)) of the junction sites NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B exhibit an inhibitory capacity towards the NS3 protease itself. Among peptide of viral origin, particular inhibitory effectiveness was evidenced in the peptides Asp-Glu-Met-Glu-Glu-Cys (IC50 = 1.1.mu.M) and Glu-Asp-Val-Val-Cys-Cys (IC50 = 5.3 .mu.M), corresponding to the P6-P1 residues, resp., of sites NS4A/NS4B and NS5A/NS5B. Sixty-nine peptide inhibitors are provided with IC50 values in the micromolar range. The peptides may be used for binding or inhibition assays of the enzymic activity of HCV NS3 protease, and in particular for the prepn. of drugs for the treatment of non-A non-B hepatitis.

IT **234757-88-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of the serine protease activity assocd. with the NS3 protein of hepatitis C virus)

L69 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:727465 HCAPLUS
DOCUMENT NUMBER: 128:13423
TITLE: Cyclization/cleavage of macrocycles by ring-closing metathesis on solid support-conformational studies
AUTHOR(S): Pernerstorfer, Josef; Schuster, Matthias; Blechert, Siegfried
CORPORATE SOURCE: Inst. Org. Chem., Tech. Univ. Berlin, Berlin, D-10623, Germany
SOURCE: Chemical Communications (Cambridge) (1997), (20), 1949-1950
CODEN: CHCOFS; ISSN: 1359-7345

PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Grubbs' ruthenium metathesis catalyst Cl2(PCy3)2Ru:CHPh (Cy = cyclohexyl) was used to investigate the catalytic cyclization/cleavage of supported tetrapeptide derivs., e.g. I (R = tritylpolystyrene support; R1 = Ph, n = 1, 8; R1 = 2-deoxy-2-acetamido-3,4,6-tri-O-acetyl-.beta.-D-glucopyranosyloxy, n = 8) to give macrocycles, e.g. II. The rate dependence on substrate conformation has been studied.

IT **199127-25-8DP**, ether with tritylpolystyrene resin
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cyclization/cleavage of resin-bound allylglycine peptides by ring-closing metathesis)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L69 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:231368 HCAPLUS
DOCUMENT NUMBER: 126:305783
TITLE: Preparation of endothelin antagonistic peptides
INVENTOR(S): Fujita, Kagari; Ihara, Masaki; Ikemoto, Fumihiko; Yano, Mitsuo; Nishikibe, Masaru; Ishikawa, Kiyofumi; Fukami, Takehiro; Hayama, Takeshi; Niiyama, Kenji; Nagase, Toshio; Mase, Toshiaki
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: U.S., 46 pp., Cont.-in-part of U.S. Ser. No. 884,642, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5614498	A	19970325	US 1992-945414	19920916
US 5470833	A	19951128	US 1994-213829	19940314
US 5444152	A	19950822	US 1994-214679	19940321
US 5496928	A	19960305	US 1994-230534	19940420
US 5691315	A	19971125	US 1995-494818	19950626

PRIORITY APPLN. INFO.:
JP 1990-149105 A 19900607
US 1991-712095 B3 19910607
JP 1991-347670 A 19911204
JP 1991-353738 A 19911218
US 1992-884642 B2 19920518

JP 1992-234207	A	19920810
US 1992-884189	B1	19920518
US 1992-945414	A2	19920916
US 1992-981424	B1	19921125
US 1994-213829	A3	19940314

OTHER SOURCE(S): MARPAT 126:305783
GI



I

AB Peptides I [A = R11O2C, R12R13NCO, R11 = alkyl, Ph; R12 = alkyl, cycloalkyl, 1-adamantyl, Ph substituted by 0-2 halo, CF3, NO2, NH2, OHCNH, pyridyl, thienyl; R13 = H, alkyl, cycloalkyl; NR12R13 = optionally substituted 5-9-membered N heterocycle contg. 0-1 S atoms and optionally benzo-fused; B = O, NR2; R2= H, alkyl; R3 = alkyl, cycloalkyl, aryl, heterocyclic, cycloalkylalkyl, arylalkyl, heterocyclylalkyl; X1 = O, NR4; R4 = H, alkyl; R5 = 3-indolylmethyl, 3-benzothienylmethyl, 1-naphthylmethyl, or benzyl contg. 0-2 OH, formyl, alkyl, alkoxy, alkoxycarbonyl, NO2, or R51COX2 groups; R51 = alkyl, alkoxy, or amino optionally substituted by alkyl; X2 = O, NR52; R52 = H, alkyl; X3 = O, S; R6 = H, alkyl or alkenyl optionally contg. OH, alkoxy, alkylthio, heterocyclyl groups; n = 0, 1; Y = CH2OH, CO2R71, CONHR72; R71 = H , alkyl; R72 = H, 1H-tetrazol-5-yl, sulfo, phosphono, alkyl optionally contg. OH, carboxyl, or sulfo] or a pharmaceutically acceptable salt thereof, inhibit the binding of endothelin to its endothelin B (ETB) receptor and are useful in treating diseases assocd. with excess prodn. or secretion of endothelin. Thus, Boc-L-Leu-D-Trp(CO2Me)-D-Nle-OH was prepd. by std. sold. peptide coupling reactions and showed 90% inhibition of binding in a 125I-endothelin-1 assay at 1.1 .mu.M, while 108 related peptides showed 18-100% inhibition at the same concn.

IT **158739-49-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of endothelin antagonistic peptides)

L69 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:58126 HCAPLUS
DOCUMENT NUMBER: 126:171876
TITLE: Enzymic oligomerization of the tetrapeptide ester allylglycine-phenylalanine-phenylalanine-allylglycine ethyl ester
AUTHOR(S): Falender, Corrine A.; Blanch, Harvey W.; Clark, Douglas S.
CORPORATE SOURCE: Department of Chemical Engineering, University of California at Berkeley, Berkeley, CA, 94720, USA
SOURCE: Biocatalysis and Biotransformation (1995), 13(2), 131-139
CODEN: BOBOEQ; ISSN: 1024-2422
PUBLISHER: Harwood
DOCUMENT TYPE: Journal
LANGUAGE: English

prob good

AB The native hydrolytic action of subtilisin Carlsberg was reversed to oligomerize the tetrapeptide ester H-Ag-Phe-Phe-Ag-OEt, contg. the unnatural amino acid L-allylglycine (Ag), in several miscible aq./org. solvent systems. Mass spectrometry indicated that the octapeptide ester

H-(Ag-Phe-Phe-Ag)2-OEt was formed in all cases and that the dodecapeptide ester H-(Ag-Phe-Phe-Ag)3-OEt was formed in one case. Addnl. mass spectrometry peaks indicated that a no. of other peptides larger than the octapeptide ester may also have been formed. IR anal. revealed that the oligopeptide products exhibit .beta.-sheet peptide folding.

IT **187279-81-8P 187279-83-0P**
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(enzymic oligomerization of a tetrapeptide ester)

IT **173723-66-5P 187279-79-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enzymic oligomerization of a tetrapeptide ester)

L69 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:554904 HCAPLUS
DOCUMENT NUMBER: 125:222458
TITLE: Preparation of peptides and peptide analogs as protease inhibitors.
INVENTOR(S): Mcdonald, Ian Alexander; Albrecht, Elisabeth; Munoz, Benito; Rowe, Blake Alan; Siegel, Robert Steven; Wagner, Steven Lee
PATENT ASSIGNEE(S): Salk Institute Biotechnology/Industrial Associates, Inc., USA
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620949	A1	19960711	WO 1996-US359	19960105
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5804560	A	19980908	US 1995-369422	19950106
US 5714471	A	19980203	US 1995-443901	19950517
US 5962419	A	19991005	US 1995-442514	19950517
US 6015879	A	20000118	US 1995-442662	19950517
US 6051684	A	20000418	US 1995-442786	19950517
US 6153171	A	20001128	US 1995-443048	19950517
CA 2209234	AA	19960711	CA 1996-2209234	19960105
AU 9646972	A1	19960724	AU 1996-46972	19960105
EP 800528	A1	19971015	EP 1996-902650	19960105
EP 800528	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11514330	T2	19991207	JP 1996-521271	19960105
AT 227305	E	20021115	AT 1996-902650	19960105
ES 2184850	T3	20030416	ES 1996-902650	19960105

PRIORITY APPLN. INFO.: US 1995-369422 A 19950106
WO 1996-US359 W 19960105
OTHER SOURCE(S): MARPAT 125:222458

AB R7QnNR6CHR5CONR4CHR3CONR2CR1R8X, RaRbCHQnNR4CHR3CONR2CR1R8X [R1, R3, R5, R8 = amino acid side chain, H, alkyl, alkenyl, alkynyl, (substituted) aryl, aralkyl, heteroaryl, etc.; R2, R4, R6, R8 = H, alkyl; R7 = alkyl, alkenyl, 9-fluorenyl, (substituted) aryl, aralkyl, aralkenyl, aralkynyl; Q = CO, O2C, SO2, HNCO; n = 0, 1; X = (CH2)rCHO, (CH2)rCN, (CH2)rCOR9,

(CH2)rCO(CH2)rCHN2, etc.; R9 = haloalkyl], were prepd. Thus, Z-Leu-Phe-Q (Q = cyclohexylalanine aldehyde), prepd. by soln. phase methods, at 40 nM inhibited formation of amyloidogenic A.beta. peptide from amyloid precursor protein in HGB 717/Swed cells by 100%.

IT **180993-77-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides and peptide analogs as protease inhibitors)

IT **180778-83-0P 180778-84-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptides and peptide analogs as protease inhibitors)

L69 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:548527 HCAPLUS
DOCUMENT NUMBER: 125:196393
TITLE: Preparation of peptide, peptide analog and amino acid analog as protease inhibitors
INVENTOR(S): Munoz, Benito; Mcdonald, Ian Alexander; Albrecht, Elisabeth
PATENT ASSIGNEE(S): The Salk Institute Biotechnology/industrial Associ, USA
SOURCE: PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620725	A2	19960711	WO 1996-US360	19960105
WO 9620725	A3	19961017		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5804560	A	19980908	US 1995-369422	19950106
US 5969100	A	19991019	US 1995-403420	19950313
AU 9646973	A1	19960724	AU 1996-46973	19960105

PRIORITY APPLN. INFO.:
US 1995-369422 A 19950106
US 1995-403420 A 19950313
WO 1996-US360 W 19960105

OTHER SOURCE(S): MARPAT 125:196393

AB The title compds. represented by formulas R7-(Q)n-NR6CHR5CONR4CHR3CONR2CR1R8X (I), RBRACH-(Q)n-NR4CHR3CONR2CR1RBX (II), and RBRACH-(Q)n-NR2CR1RBX (III) [R1 is preferably 2-Me propene, 2-butene, norleucine; R2, R4, and R8 are each independently Me or ethyl; R3 is preferably iso-Bu or phenyl; R5 is preferably isobutyl; R6 is H or methyl; R7-(Q)n is preferably benzyloxycarbonyl or acetyl; Q is preferably CO; RB is preferably iso-butyl; RA = (T)m-(D)m-R1, in which T is preferably oxygen or carbon, and D is preferably a mono-unsatd. C3-4 alkenyl; X is an alc., particularly a secondary alc.], useful as protease inhibitors (no data), are prepd. A method for inhibiting a protease comprises contacting cells with a protease-inhibiting amt. of the compd. I, II, or III. A method for (1) treating a neurodegenerative disease (e.g. Alzheimer's disease, cognition deficits, Downs Syndrome, cerebral hemorrhage with amyloidosis, dementia pugilistica, and head trauma) characterized by the cerebral deposition of amyloid and (2) treating a patient suffering from a

disease characterized by a degrdn. of the neuronal cytoskeleton resulting from a thrombolytic or hemorrhagic stroke comprises administering to the patient a therapeutically effective amt. of the compd. I, II, or III. Thus, Z-Leu-Leu-OH was condensed with Et 2-amino-4-methyl-4-pentenoate hydrochloride (prepn. given) using HOBT, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and Et3N in CH2Cl2 to give 47.3% Z-Leu-Leu-NHCH(CO2Et)CH2CMe:CH2 as a mixt. of diastereomers, which was reduced by LiBH4 in EtOAc at 0.degree. for 30 min to give 85.6% Z-Leu-Leu-NHCH(CH2OH)CH2CMe:CH2 as a mixt. of diastereomers.

IT **180778-83-0P 180778-84-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of peptides or its analogs and amino acid analogs as protease inhibitors for disease therapy)

L69 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:434890 HCAPLUS
DOCUMENT NUMBER: 125:59118
TITLE: Synthesis and Structure-Activity Relationships of 2-Substituted D-Tryptophan-Containing Peptidic Endothelin Receptor Antagonists: Importance of the C-2 Substituent of the D-Tryptophan Residue for Endothelin A and B Receptor Subtype Selectivity
AUTHOR(S): Fukami, Takehiro; Yamakawa, Takeru; Niiyama, Kenji; Kojima, Hisaki; Amano, Yuuka; Kanda, Fuyuko; Ozaki, Satoshi; Fukuroda, Takahiro; Ihara, Masaki; et al.
CORPORATE SOURCE: Tsukuba Research Institute, Banyu Pharmaceutical Company Ltd., Tsukuba, 300-33, Japan
SOURCE: Journal of Medicinal Chemistry (1996), 39(12), 2313-2330
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide deriv. ET receptor antagonists, represented by BQ-788, are described. The introduction of D-tryptophan analogs with C-2 substituents in these peptide ET antagonists resulted in potent ET receptor antagonists with various ETA/ETB subtype selectivity. Combined ETA/ETB receptor antagonists were found in both cyclic pentapeptide and linear tripeptide series with 2-halo- and 2-methyl-D-tryptophans. In contrast, compds. with 2-cyano-D-tryptophan were ETB receptor-selective antagonists. The C-2 substituent of the D-tryptophanyl residue appeared to be very important for the discrimination of ETA/ETB subtype selectivity of the antagonists. The potent ET receptor antagonists with various ETA/ETB subtype selectivity synthesized in this study may be useful tools for elucidating the physiol. and pathophysiol. roles of ET and ET receptors.

IT **178034-94-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-activity substituted tryptophan-contg. peptide and cyclopeptide endothelin receptor antagonists)

L69 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:968443 HCAPLUS
DOCUMENT NUMBER: 124:176881
TITLE: Enzymic synthesis of peptides containing unnatural amino acids
AUTHOR(S): Fernandez, M. M.; Margot, A. O.; Falender, C. A.; Blanch, H. W.; Clark, D. S.

CORPORATE SOURCE: Chemical Engineering Department, University of California at Berkeley, Berkeley, CA, USA
SOURCE: Enzyme and Microbial Technology (1995), 17(11), 964-71
CODEN: EMTED2; ISSN: 0141-0229
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several proteases were studied as potential catalysts for the enzymic synthesis of oligopeptides contg. the unnatural amino acid allylglycine, the overall objective being the synthesis of a reactive tetrapeptide that could be chem. polymd. into a potentially biocompatible or biodegradable material. Com. available enzymes were screened for esterase activity toward allylglycine Me ester (DL-AgOMe) to identify potential catalysts for dipeptide synthesis. Proteases from Aspergillus oryzae and Aspergillus sojae, pronase E and protease Nagarse synthesized the protected dipeptide Cbz-allylglycine-phenylalaninamide (Cbz-L-Ag-L-PheNH2) from Cbz-DL-AgOMe and L-PheNH2. However, the same enzymes were not able to catalyze the synthesis of Cbz-phenylalanine-allylglycine Et ester (Cbz-L-Phe-L-AgOEt). Thus, although these enzymes could use allylglycine as the acyl donor they could not employ it as the acyl acceptor in peptide synthesis. In contrast, chymotrypsin was able to use allylglycine Et ester (DL-AgOEt) as the acyl acceptor in the synthesis of Cbz-L-Phe-L-AgOEt, but was not able to synthesize Cbz-L-Ag-L-PheNH2. Cbz-allylglycine-phenylalanine and phenylalanine-allylglycine Et ester served as substrates for the thermolysin-catalyzed synthesis of the tetrapeptide Cbz-L-Ag-L-Phe-L-Phe-L-AgOEt.

IT **173723-66-5P**
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(enzymic synthesis of allylglycine-contg. peptides)

L69 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:580487 HCAPLUS
DOCUMENT NUMBER: 122:315099
TITLE: Preparation of peptides as novel endothelin antagonists
INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Ihara, Masaki; Nishikibe, Masaru; Yano, Mitsuo
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419368	A1	19940901	WO 1994-JP194	19940209
W: AU, CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9460103	A1	19940914	AU 1994-60103	19940209
JP 07041498	A2	19950210	JP 1994-35239	19940209

PRIORITY APPLN. INFO.: JP 1993-57814 19930223
JP 1993-144216 19930524
WO 1994-JP194 19940209

OTHER SOURCE(S): MARPAT 122:315099
GI



I



AB Peptides represented by formula [I; R1O2C (wherein R1 = lower alkyl or aryl) or R21R22NCO (wherein R21 = lower alkyl, cycloalkyl, cycloalkylalkyl, adamantyl, or optionally substituted aryl or heteroaryl; R22 = H, lower optionally substituted by OH, cycloalkyl, cycloalkylalkyl or R21R22N = C4-8 5- to 9-membered ring N-contg. satd. heterocyclyl wherein any methylene group not adjacent to the N atom may be replaced with S and any 1-4 H atoms on the heterocyclyl group may be independently substituted by lower alkyl or lower hydroxyalkyl or it may form a benzo-fused ring at two adjacent C atoms); R3 = H, lower alkyl; R4 = lower alkylthioalkyl, alkenyl, cycloalkyl or cycloalkyl-lower alkyl optionally substituted by C1-4 lower, alkyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl; X = halo, lower alkyl; R5 = H, lower alkyl; R6 = H, HO, lower alkoxy or alkylthio, lower alkyl or alkenyl optionally having aryl or heteroaryl substituent; n = 0,1; Y = CH2OH, CO2R71 (wherein R71 = H, lower alkyl), CONR72R73 (wherein R72, R73 = H, aryl, heteroaryl, lower alkyl optionally substituted with OH, CO2H, or SO3H), 1H-tetrazol-5-yl, SO3H, P(O)(OH)2] or analogs thereof are prepd. These compds. I exhibit antagonism against reactions of an endothelin, one of the intrinsic, physiol. active peptides, via endothelin A and B receptors and hence are useful as a remedy for various diseases wherein the endothelin participates, including hypertension, pulmonary hypertension, Raynaud's disease, asthma, acute kidney failure, myocardial infarction, angina pectoris, etc. Thus, Nim-(tert-butoxylcarbonyl)-2-chloro-D-tryptophyl-D-norleucine tert-Bu ester was condensed with N-2,6-dimethylpiperidinocarbonyl-L-valine by using 1-hydroxy-1H-benzotriazole hydrate and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 and deprotected with CF3CO2H at room temp. to give title compd. I (A = Q, R3 = R5 = H, R4 = CHMe2, R6 = Bu, X = Cl, n = 0, Y = CO2H) (II). II and I (A = Q, R3 = R5 = H, R4 = CHMe2, R6 = n-Pr, X = Br, n = 0, Y = CO2H) at 1.1 .mu.M in vitro inhibited 90 and 100%, resp., the binding of [125I]endothelin to endothelin receptor subtype-ETA prepn. from pig aorta smooth muscle tissue and 99 and 100% resp., that to endothelin receptor subtype-ETB prepn. from pig cerebellum.

IT **163446-08-0P 163446-09-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as endothelin receptor antagonists)

L69 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:681232 HCAPLUS
DOCUMENT NUMBER: 121:281232
TITLE: Preparation of peptide endothelin antagonists
INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Nagase, Toshio; Mase, Toshiaki; Ihara, Masaki; Yano, Mitsuo; Nishikibe, Masaru
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: Can. Pat. Appl., 182 pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2084163	AA	19930605	CA 1992-2084163	19921130
EP 555537	A2	19930818	EP 1992-120225	19921126
EP 555537	A3	19941102		
EP 555537	B1	20001102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 197305	E	20001115	AT 1992-120225	19921126
AU 9229838	A1	19930610	AU 1992-29838	19921202
AU 657585	B2	19950316		
JP 06107680	A2	19940419	JP 1992-349905	19921202
JP 3398992	B2	20030421		

PRIORITY APPLN. INFO.: JP 1991-347670 A 19911204
JP 1991-353738 A 19911218
JP 1992-234207 A 19920810

OTHER SOURCE(S): MARPAT 121:281232
GI



I



II

AB Title compds. [I; A = R11O2C, R12R13NCO; R11 = alkyl, Ph; R12 = alkyl, cycloalkyl, 1-adamantyl, (substituted) Ph; R13 = H, alkyl, cycloalkyl; R12R13N = (substituted) 5-9-membered heterocyclic ring; B = O, NR2; R2 = H, alkyl; R3 = alkyl, cycloalkyl, aryl, heterocyclyl, cycloalkyl, aryl, heterocyclylalkyl; X1 = O, NR3; R5 = 3-indolylmethyl, 3-benzothienylmethyl, 1-naphthylmethyl, (substituted) PhCH2; R6 = H, alkyl, (substituted) alkenyl; n = 0,1; Y = hydroxymethyl, CO2R71, CONHR72, tetrazolyl, sulfo, phosphono; R71 = H, alkyl; R72 = H, (substituted) alkyl], were prepd. Thus, title compd. I, prepd. by soln. phase methods, antagonized endothelin-3-induced contraction of rabbit pulmonary artery with PA2 = 6.7.

IT **158739-49-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as endothelin antagonist)

L69 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:681212 HCAPLUS
DOCUMENT NUMBER: 121:281212
TITLE: Introduction of Allylic Side Chains onto Peptides by Pd(0)-Catalyzed "Ester Enolate Claisen Rearrangement"
AUTHOR(S): Kazmaier, Uli
CORPORATE SOURCE: Organisch-Chemisches Institut, Universitaet Heidelberg, Heidelberg, D-69120, Germany
SOURCE: Journal of Organic Chemistry (1994), 59(22), 6667-70
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:281212

AB Peptide allylic esters, e.g. Z-L-Phe-Gly-OCH2CMe:CH2, undergo an ester enolate Claisen rearrangement upon treatment with LDA in the presence of various metal salts to give diastereomeric mixts. Z-L-Phe-NHCH(CH2CMe:CH2)CO2Me after esterification with CH2N2. Best results are obtained using zinc chloride. In the presence of a catalytic amt. of Pd(0) the rearrangement products are formed in high yields. Addn. of Pd(II) has no significant influence on the yield and stereoselectivity of the reaction. In contrast to the rearrangement without Pd(0), the catalyzed reaction probably proceeds via intermol. allylic alkylation as is shown in a cross expt. of different allylic esters. The methodol. is not limited to dipeptides, but can also be applied to larger peptides as is illustrated in the rearrangement of tripeptide Z-L-Phe-L-Ala-Gly-OCH2CH:CH2 to Z-L-Phe-L-Ala-NHCH(CH2CH:CH2)CO2Me after esterification. No epimerization of chiral centers is obsd. under the reaction conditions used.

IT **158840-19-8P 158840-20-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(introduction of allylic side chains onto peptides by palladium-catalyzed ester enolate Claisen rearrangements)

L69 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:164906 HCAPLUS
DOCUMENT NUMBER: 120:164906
TITLE: Preparation of cyclic calcitonin derivatives and their hypocalcemic activity
INVENTOR(S): Mena, Renzo; Brugnolotti, Manuela; Farina, Carlo; Pinza, Mario
PATENT ASSIGNEE(S): Smithkline Beecham Farmaceutici S.p.A., Italy
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9315106	A1	19930805	WO 1993-EP130	19930120
W: AU, CA, JP, KR, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9334506	A1	19930901	AU 1993-34506	19930120
EP 624163	A1	19941117	EP 1993-903212	19930120
EP 624163	B1	19980325		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07506809	T2	19950727	JP 1993-512910	19930120

PRIORITY APPLN. INFO.: GB 1992-1819 19920124
WO 1993-EP130 19930120

OTHER SOURCE(S): MARPAT 120:164906
GI



I



Ser(t-Bu)-Asn-Leu-Ser(t-Bu)-Thr(t-Bu)-NH-CH-CO-Val-Leu-Gly-OH

II



Ser-Asn-Leu-Ser-Thr-NH-CH-CO-Val-Leu-Gly-Lys-Leu-Ser-Gln-

-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-

-Ala-Gly-Thr-Pro-NH_2 @ 4 TFA

III

AB The title compds. [I; X-Y = CH:CH, C.tplbond.C; A = a segment of naturally occurring calcitonin contg. 2-6 amino acid units; B = a segment of naturally occurring calcitonin contg. 8-32 amino acid units; R1-R4 = H, C1-4 alkyl] are prepd. Thus, N-hydroxybenzotriazole, DCC, and 4-(dimethylamino)pyridine were added to a soln. of the cyclic peptide II (prepn. given) in DMF; after 10 min at 0.degree., H-Lys(BOC)Leu-Ser(t-Bu)-Gln-Glu(OtBu)-Leu-His(Trt)-Lys(BOC)-Leu-Gln-Thr(t-Bu)-Tyr(t-Bu)-Pro-Arg(Mtr)-Thr(t-Bu)-Asp(OtBu)-Val-Gly-Ala-Gly-Thr(tBu)-Pro-NH2 (also prepd.) was added, the reaction mixt. was maintained at 0.degree. for 1 h and then at room temp. overnight to give, after deprotection, the title compd. III. Rats showed 10.16.+-.0.8 mg Ca per 100 mL serum 1 h after an i.v. administration of 3 ng/Kg of this. Formulations contg. III for nasal, sublingual, buccal, rectal, or vaginal administration are given.

IT **152874-96-9P 152874-97-0P 152983-37-4P 152985-16-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for hypocalcemics)

L69 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:77620 HCAPLUS
DOCUMENT NUMBER: 120:77620
TITLE: Synthetic studies on antifungal cyclic peptides, echinocandins. Stereoselective total synthesis of echinocandin D via a novel peptide coupling
AUTHOR(S): Kurokawa, Natsuko; Ohfune, Yasufumi
CORPORATE SOURCE: Suntory Inst. Bioorg. Res., Osaka, 618, Japan
SOURCE: Tetrahedron (1993), 49(28), 6195-222
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:77620
GI



I

AB Synthetic studies on the novel fungicidal oligopeptides, echinocandin C (I; R1 = OH) and D (I; R1 = H), are described. The constituent amino acids (3S,5S)-3-hydroxy-4-methyl-L-proline, (3R)-hydroxy-L-homotyrosine, hydroxyproline, and 4,5-dihydroxyornithine were synthesized in a stereocontrolled manner from chiral starting materials. The coupling of these amino acids was characterized by the use of unprotected amino acid as the C-terminal and 2-pyridyl thiol ester as the N-terminal, and the coupling was performed in the presence of 1-(trimethylsilyl)imidazole or a catalytic amt. of tert-amine to give C-terminal free dipeptides, which were converted a common pentapeptide intermediate for the synthesis of I. The synthesis of I (R1 = H) was achieved by the cyclization of a hexapeptide intermediate.

IT **108543-90-4P 124390-39-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L69 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:560765 HCAPLUS
DOCUMENT NUMBER: 119:160765
TITLE: Substituted penta- and hexapeptides as potent inhibitors of herpes simplex virus type 2 ribonucleotide reductase
AUTHOR(S): Chang, L. L.; Hannah, J.; Ashton, W. T.; Rasmusson, G. H.; Ikeler, T. J.; Patel, G. F.; Garsky, V.; Uncapher, C.; Yamanaka, G.; et al.
CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(10), 1207-12
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Structural modifications of the Tyr, Asn, and Leu residues of H-Tyr-Val-Val-Asn-Asp-Leu-OH, a peptide which is equipotent to H-Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu-OH (I) in the inhibition of herpes simplex virus type 2 ribonucleotide reductase (HSV-2 RR), have produced peptides which are as much as 90- to 120-times as potent as I in vitro against HSV-2 RR. The chem. and the structure activity relationships of these inhibitors are described.

IT **150048-49-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and inhibition by, of herpes simplex virus type 2 ribonucleotide reductase)

L69 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:179812 HCAPLUS
DOCUMENT NUMBER: 112:179812
TITLE: Stereoselective hydroxylation of a peptide side chain. The synthesis of the echinocandin right-half equivalent
AUTHOR(S): Sakaitani, Masahiro; Ohfune, Yasufumi
CORPORATE SOURCE: Suntory Inst. Bioorg. Res., Osaka, 618, Japan
SOURCE: Tetrahedron Letters (1989), 30(17), 2251-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:179812
GI



I

AB Highly stereoselective synthesis of the functionalized tripeptide I, equiv. to the echinocandin C right half from the simple and rather sym. tripeptide Me3CO2C-Alg-Thr(SiMe2CMe3)-Alg-ONa (II; Alg = L-allylglycine) has been accomplished based on the halolactonization from the C-terminal of II and the cyclic carbamate formation from the N-terminal of II.
IT **108543-87-9P 108543-90-4P 126116-33-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromolactonization of, stereochem. of)
IT **108568-41-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L69 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:36461 HCAPLUS
DOCUMENT NUMBER: 112:36461
TITLE: Preparation of peptides as intermediates for agrochemicals, pharmaceuticals, and flavoring agents
INVENTOR(S): Ofuna, Yasushi; Kurokawa, Natsuko; Hori, Keiko; Sakaitani, Masahiro
PATENT ASSIGNEE(S): Suntory, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62084099	A2	19870417	JP 1985-225498	19851009

PRIORITY APPLN. INFO.: JP 1985-225498 19851009
GI



II



III

AB R3O2CCHR1NHCOCHR8NHR2 [I; R1, R8 = H, alkyl, alkenyl, Ph, aralkyl, etc.; R2 = H, protecting group, (protected) amino acid residue; R3 = H, alkyl], useful as intermediates for agrochems., pharmaceuticals, and flavoring agents, are prepd. via reaction of H2NCHR5CO2H [R5 = H, alkyl, alkenyl, etc.] with (trialkylsilyl)imidazole and treating the product with amino acid esters of 2-mercaptopyridine II [R6 = H, alkyl, etc.; R7 = protecting group, (protected) amino acid residue] optionally followed by deprotection and alkylation. L-Allylglycine in DMF was reacted with (trimethylsilyl)imidazole at room temp. for 1 h, II (R6 = Me2CH, R7 = PhCH2O2C) added, and the resulting mixt. stirred at room temp. for 2 h to give peptide III.

IT **124390-39-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for agrochems., pharmaceuticals, and flavorants)

L69 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:407620 HCAPLUS
DOCUMENT NUMBER: 107:7620
TITLE: A method for peptide synthesis
INVENTOR(S): Ofuna, Yasushi; Kurokawa, Natsuko; Hori, Keiko; Sakaitani, Masahiro
PATENT ASSIGNEE(S): Suntory, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62059295	A2	19870314	JP 1985-199285	19850909

PRIORITY APPLN. INFO.: JP 1985-199285 19850909

AB R1CH(CO2R3)NHCOCHR6NHR2 [I; R1, R6 = (un)protected C1-7 hydroxyalkyl, (un)protected C7-9 hydroxyaralkyl, C1-10 alkyl, C2-6 alkenyl, Ph, C7-9 aralkyl, C2-6 alkylthioalkyl, (un)protected C1-4 mercaptoalkyl, indolylmethyl; R2 = H, NH2 protecting group, COCHR1NHR4 where R4 = H or NH2 protecting group; R3 = H or alkyl] were prepd. by silylation of unprotected amino acids R1CH(NH2)CO2H with a trialkylsilylimidazole, e.g., (tert-butyldimethylsilyl)imidazole, (trimethylsilyl)imidazole, (triethylsilyl)imidazole, (dimethylphenylsilyl)imidazole and (tert-butyldiphenylsilyl)imidazole and reaction of the intermediate R1CH(NHR5)CO2R5 (R5 = trialkylsilyl) with an active ester R6CH(NHR2)C(O)SQ (Q = pyridin-2-yl). This method prevents racemization of amino acids and peptides and decompn. of the active esters. .alpha.-Amino acids can be used without protective groups. Thus, a suspension of 230 mg L-allylglycine in DMF was reacted with 560 mg trimethylsilylimidazole for 1 h and 550 mg N-(benzyloxycarbonyl)valine 2-pyridylthio ester in DMF was added. The mixt. was allowed to react at room temp. for 2 h to give 88% N-(benzyloxycarbonyl)-L-valyl-2-amino-4-pentenoic acid.

IT **108543-87-9P 108543-90-4P 108568-41-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, via peptide coupling of tris(trialkylsilyl)amino acid with amino acid pyridylthio ester deriv.)

L69 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:15096 HCAPLUS
DOCUMENT NUMBER: 106:15096
TITLE: Penicillin biosynthesis: structure-reactivity profile of allenic substrates for isopenicillin N synthetase
AUTHOR(S): Baldwin, Jack E.; Adlington, Robert M.; Basak, Amit; Ting, Hong Hoi
CORPORATE SOURCE: Dyson Perrins Lab., Univ. Oxford, Oxford, OX1 3QY, UK
SOURCE: Journal of the Chemical Society, Chemical Communications (1986), (16), 1280-1
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

may be good

AB The allene-contg. peptides (I) (R = L-.alpha.-aminoadipoyl, R1 = CH:C:CH2, CH2CH:C:CH2) were prepd. and evaluated as substrates for isopenicillin N synthetase: the formation of penam, cepham, and dienyl products is consistent with a desaturative ring closure mechanism.
IT **105988-86-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ring closure by isopenicillin N synthetase)

L69 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1973:537474 HCAPLUS
DOCUMENT NUMBER: 79:137474
TITLE: Hormone-receptor relations. Synthesis and properties of [phenylalanine2.(4,5-dehydro-4,5-ditritio)norvaline4]adrenocorticotropin (1-24)-tetracosapeptide
AUTHOR(S): Schwyzer, Robert; Karlaganis, Georg
CORPORATE SOURCE: Inst. Molekularbiol. Biophys., Eidg. Tech. Hochsch., Zurich, Switz.
SOURCE: Justus Liebigs Annalen der Chemie (1973), (8), 1298-309
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
AB The T-labeled ACTH analog [Phe2,Nva4-4,5-t2]ACTH1-24 (I) was prepd. from protected [Phe2,Agl4]-ACTH1-24 (Agl = L-allylglycine) by catalytic tritiation of the double bond and subsequent removal of the protecting groups by HF. The unlabeled [Phe2,Nva4] analog (II) was similarly prepd. I and II were completely active hormonal agonists in isolated rat lipocytes and adrenal cortex cells but 10-fold less active than ACTH1-24 with the natural sequence.
IT **50299-19-9P 50299-20-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

```
=> fil caold;s l68
FILE 'CAOLD' ENTERED AT 17:03:58 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REG1stRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.


L70           0 L68

=> fil reg
FILE 'REGISTRY' ENTERED AT 17:04:06 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     1 JUN 2003  HIGHEST RN 523977-56-2
DICTIONARY FILE UPDATES:    1 JUN 2003  HIGHEST RN 523977-56-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> d ide can l68 tot .

L68  ANSWER 1 OF 43  REGISTRY  COPYRIGHT 2003 ACS
RN   509091-70-7  REGISTRY
CN   L-Norvaline, N-acetyl-3-[(1S)-2,2'-dimethoxy-3'-(2-propenyl)[1,1'-
     binaphthalen]-3-yl]alanyl-N6-[(1,1-dimethylethoxy)carbonyl]-D-lysyl-4,5-
     didehydro-, methyl ester (9CI)  (CA INDEX NAME)
MF   C47 H58 N4 O9
SR   CA
LC   STN Files:   CA, CAPLUS
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:304509

L68 ANSWER 2 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484024-62-6 REGISTRY
CN L-Norvaline, N-acetyl-3-[2,2'-dimethoxy-3'-(2-propenyl)[1,1'-binaphthalen]-3-yl]alanyl-D-arginyl-4,5-didehydro-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H50 N6 O7 . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HCl

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 3 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484024-21-7 REGISTRY
CN L-Norvaline, N-acetyl-O-2-propenyl-L-tyrosyl-N6-(aminoiminomethyl)-L-lysyl-4,5-didehydro-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H40 N6 O6 . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 4 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484024-20-6 REGISTRY
CN L-Norvaline, N-acetyl-O-2-propenyl-L-tyrosyl-N6-[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]-L-lysyl-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C37 H56 N6 O10
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 5 OF 43 REGISTRY COPYRIGHT 2003 ACS

RN 484024-17-1 REGISTRY
CN L-Norvaline, N-acetyl-O-2-propenyl-L-tyrosyl-L-lysyl-4,5-didehydro-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H38 N4 O6 . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 6 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484024-16-0 REGISTRY
CN L-Norvaline, N-acetyl-O-2-propenyl-L-tyrosyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H46 N4 O8
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 7 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484023-99-6 REGISTRY
CN L-Norvaline, N-acetyl-3-[2,2'-dimethoxy-3'-(2-propenyl)[1,1'-binaphthalen]-3-yl]alanyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C56 H68 N6 O10 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 8 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484023-96-3 REGISTRY
CN L-Norvaline, N-acetyl-3-[2,2'-dimethoxy-3'-(2-propenyl)[1,1'-binaphthalen]-3-yl]alanyl-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C57 H60 N4 O9
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 9 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 484023-93-0 REGISTRY
CN L-Norvaline, N-acetyl-3-[2,2'-dimethoxy-3'-(2-propenyl)[1,1'-binaphthalen]-3-yl]alanyl-N6-[(1,1-dimethylethoxy)carbonyl]-D-lysyl-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C47 H58 N4 O9
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:90077

L68 ANSWER 10 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 476681-78-4 REGISTRY
CN L-Norvaline, N2-acetyl-L-arginyl-L-glutaminyl-L-seryl-L-arginyl-L-seryl-4,5-didehydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 377: PN: WO02095007 SEQID: 527 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C30 H53 N13 O11
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:16587

L68 ANSWER 11 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 476681-18-2 REGISTRY
CN Norvaline, N2-acetyl-L-glutaminylglycyl-L-arginyl-L-seryl-L-seryl-4,5-didehydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 325: PN: WO02095007 SEQID: 453 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C26 H44 N10 O11
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:16587

L68 ANSWER 12 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 476681-17-1 REGISTRY
CN Norvaline, N2-acetyl-L-glutaminylglycyl-L-arginyl-L-seryl-D-seryl-4,5-didehydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 324: PN: WO02095007 SEQID: 452 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C26 H44 N10 O11
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:16587

L68 ANSWER 13 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 444990-64-1 REGISTRY
CN L-Norvaline, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-.beta.-phenyl-L-phenylalanyl-L-.alpha.-glutamyl-3-cyclohexyl-L-alanyl-4,5-didehydro- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C45 H58 N6 O14
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:149812

L68 ANSWER 14 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 272435-37-7 REGISTRY
CN Norvaline, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-4,5-didehydro- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH
MF C31 H46 N6 O16 S
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:12727

L68 ANSWER 15 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 246242-59-1 REGISTRY
CN Leucine, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-leucyl-4,5-didehydro-, ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 131:286829

L68 ANSWER 16 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 234757-88-1 REGISTRY
CN L-Norvaline, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-4,5-didehydro- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C29 H44 N6 O15 S
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 131:127188

L68 ANSWER 17 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 199127-25-8 REGISTRY
CN 4-Tridecenoic acid, 4,5-didehydro-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-norvalyl-L-alanyl-L-phenylalanyl-2-amino-13-hydroxy-, methyl ester, (2S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C46 H58 N4 O8
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 128:13423

L68 ANSWER 18 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 187279-83-0 REGISTRY
CN L-Norvaline, 4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-L-norvalyl-4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-L-norvalyl-4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-, ethyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C86 H102 N12 O13
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 126:171876

L68 ANSWER 19 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 187279-81-8 REGISTRY
CN L-Norvaline, 4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-L-norvalyl-4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-, ethyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C58 H70 N8 O9
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 126:171876

L68 ANSWER 20 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 187279-79-4 REGISTRY
CN L-Norvaline, 4,5-didehydro-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-, ethyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C30 H38 N4 O5
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 126:171876

L68 ANSWER 21 OF 43 REGISTRY COPYRIGHT 2003 ACS

RN 180993-77-5 REGISTRY
CN Leucine, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-leucyl]-L-leucyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN DL-Leucine, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-leucyl]-L-leucyl]-, ethyl ester, monohydrochloride
FS STEREOSEARCH
MF C28 H43 N3 O6 . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (246242-59-1)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 125:222458

L68 ANSWER 22 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 180778-84-1 REGISTRY
CN L-Leucine, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-leucyl]-L-leucyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N3 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 125:222458

REFERENCE 2: 125:196393

L68 ANSWER 23 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 180778-83-0 REGISTRY
CN D-Leucine, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-leucyl]-L-leucyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N3 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 125:222458

REFERENCE 2: 125:196393

L68 ANSWER 24 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 178034-94-1 REGISTRY
CN D-Norvaline, N-[2-bromo-N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-L-leucyl]-D-tryptophyl]-4,5-didehydro-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H42 Br N5 O5
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 125:59118

L68 ANSWER 25 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 173723-66-5 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[(phenylmethoxy)carbonyl]-L-norvalyl-L-phenylalanyl-L-phenylalanyl-4,5-didehydro-, ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Norvaline, 4,5-didehydro-N-[N-[N-[4,5-didehydro-N-[(phenylmethoxy)carbonyl]-L-norvalyl]-L-phenylalanyl]-L-phenylalanyl]-, ethyl ester
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C38 H44 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 126:171876

REFERENCE 2: 124:176881

L68 ANSWER 26 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 163446-09-1 REGISTRY
CN D-Norvaline, N-[2-bromo-N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-L-leucyl]-D-tryptophyl]-4,5-didehydro- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H42 Br N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 122:315099

L68 ANSWER 27 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 163446-08-0 REGISTRY
CN D-Norvaline, N-[2-bromo-N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-L-leucyl]-D-tryptophyl]-4,5-didehydro-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H44 Br N5 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 122:315099

L68 ANSWER 28 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 158840-20-1 REGISTRY
CN D-Norvaline, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-phenylalanyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C26 H31 N3 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 121:281212

L68 ANSWER 29 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 158840-19-8 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[N-[(phenylmethoxy)carbonyl]-L-phenylalanyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H31 N3 O6
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 121:281212

L68 ANSWER 30 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 158739-49-2 REGISTRY
CN D-Norvaline, 4,5-didehydro-N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H40 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 126:305783

REFERENCE 2: 121:281232

L68 ANSWER 31 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 152985-16-5 REGISTRY
CN L-Threoninamide, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-seryl-L-asparaginyl-L-leucyl-O-(1,1-dimethylethyl)-L-seryl-N-[6-carboxy-1-(methoxycarbonyl)-3-hexenyl]-O-(1,1-dimethylethyl)-, (E)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF C56 H83 N7 O15
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:164906

L68 ANSWER 32 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 152983-37-4 REGISTRY
CN L-Threoninamide, O-(1,1-dimethylethyl)-L-seryl-L-asparaginyl-L-leucyl-O-(1,1-dimethylethyl)-L-seryl-N-[6-carboxy-1-(methoxycarbonyl)-3-hexenyl]-O-(1,1-dimethylethyl)-, (E)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF C41 H73 N7 O13
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:164906

L68 ANSWER 33 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 152874-97-0 REGISTRY
CN L-Threoninamide, O-(1,1-dimethylethyl)-L-seryl-L-asparaginyl-L-leucyl-O-(1,1-dimethylethyl)-L-seryl-N-[6-carboxy-1-(methoxycarbonyl)-3-hexenyl]-O-(1,1-dimethylethyl)-, [S-(Z)]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF C41 H73 N7 O13
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:164906

L68 ANSWER 34 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 152874-96-9 REGISTRY
CN L-Threoninamide, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-seryl-L-asparaginyl-L-leucyl-O-(1,1-dimethylethyl)-L-seryl-N-[6-carboxy-1-(methoxycarbonyl)-3-hexenyl]-O-(1,1-dimethylethyl)-, [S-(Z)]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF C56 H83 N7 O15
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



—CH_2—CH═CH—CH_2—CH_2—CO_2H

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:164906

L68 ANSWER 35 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 150048-49-0 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[N2-[N-(N-L-tyrosyl-L-valyl)-L-valyl]-L-asparaginyl]-L-.alpha.-aspartyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C32 H47 N7 O11
SR CA
LC STN Files: CA, CAPLUS

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 119:160765

L68 ANSWER 36 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 126116-33-4 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-L-threonyl]-, monosodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H45 N3 O7 Si . Na

SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)
CRN (108543-90-4)

Absolute stereochemistry.



● Na

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 112:179812

L68 ANSWER 37 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 124390-39-2 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-L-threonyl]-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H47 N3 O7 Si
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)

2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:77620

REFERENCE 2: 112:36461

L68 ANSWER 38 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 108568-41-8 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl]-L-threonyl]-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
DR 126116-38-9
MF C20 H33 N3 O7
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 112:179812

REFERENCE 2: 107:7620

L68 ANSWER 39 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 108543-90-4 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl]-O-[(1,1-dimethylethyl)dimethylsilyl]-L-threonyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H45 N3 O7 Si
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 120:77620

REFERENCE 2: 112:179812

REFERENCE 3: 107:7620

L68 ANSWER 40 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 108543-87-9 REGISTRY
CN L-Norvaline, 4,5-didehydro-N-[N-[4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl]-L-threonyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H31 N3 O7
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 112:179812

REFERENCE 2: 107:7620

L68 ANSWER 41 OF 43 REGISTRY COPYRIGHT 2003 ACS

RN 105988-86-1 REGISTRY
CN L-Cysteinamide, 5-carboxy-L-norvalyl-N-(1-carboxy-3,4-pentadienyl)-, (R)-(9CI) (CA INDEX NAME)
MF C15 H23 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 106:15096

L68 ANSWER 42 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 50299-20-2 REGISTRY
CN L-Norleucine, 4,5-didehydro-N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-seryl]-L-phenylalanyl]-L-seryl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C25 H36 N4 O9
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 79:137474

L68 ANSWER 43 OF 43 REGISTRY COPYRIGHT 2003 ACS
RN 50299-19-9 REGISTRY
CN L-Norleucine, 4,5-didehydro-N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-seryl]-L-phenylalanyl]-L-seryl]-, methyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C26 H38 N4 O9
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 79:137474